Affymax (AFFY) wins approval for its drug to treat anemic kidney patients -Bloomberg
Tweet Send to a FriendGet Alerts AFFY Hot Sheet
Down)
Trade AFFY Now!
Affymax (Nasdaq: AFFY) wins approval for its drug to treat anemic kidney patients
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Affymax (AFFY) Sees Early Weakness
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Real Goods Solar (RSOL) Goes Parabolic
Create E-mail Alert Related Categories
FDA, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
